Connect with us

Hi, what are you looking for?

Jewish Business News

IPOs

Universal flu vaccine co BiondVax mulls NY IPO

BiondVax is exploring two options – either a conventional offering or listing American Depositary Receipts.

Biondvax-vaccine3

 

Universal flu vaccine developer BiondVax Pharmaceuticals Ltd. (TASE:BNDX) is mulling a Wall Street IPO, sources inform “Globes.” The company has a market cap of NIS 42 million on the Tel Aviv Stock Exchange (TASE).

BiondVax is exploring two options either a conventional offering or listing American Depositary Receipts (ADR) for trading. The company will be required to file a prospectus with the US Securities and Exchange Commission (SEC) and the bookrunner is likely to be Aegis. The company value is likely to be close to its present market cap in Tel Aviv. After trading on the market for a while the company may try for a higher value.

Biondvax’s universal flu vaccine has already undergone a successful Phase II trial (efficacy study) and has received approval for a Phase II clinical trial in Israel, which will take place in 2015.

The company lose NIS 4.1 million in the first half of 2014 and has no revenue, and cash reserves of NIS 14.1 million. Biondvax was founded by its CEO Ron Babecoff.

 

Published by Globes [online], Israel business news – www.globes-online.com

Newsletter



Advertisement

You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

Entertainment

The Movie The Professional is what made Natalie Portman a Lolita.

Travel

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.

Advertisement